genevieve deblois - Publications

Affiliations: 
2016-2019 Princess Margaret Cancer Centre 

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Kohan AA, Lupien M, Cescon D, Deblois G, Ventura M, Metser U, Veit-Haibach P. Detection of metabolic adaptation in a triple-negative breast cancer animal model with [F]choline-PET imaging as a surrogate for drug resistance. European Journal of Nuclear Medicine and Molecular Imaging. PMID 38095672 DOI: 10.1007/s00259-023-06546-0  0.587
2023 Cameron S, Deblois G, Hawley JR, Qamra A, Zhou S, Tonekaboni SAM, Murison A, Van Vliet R, Liu J, Locasale JW, Lupien M. Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer. Oncogene. PMID 37020039 DOI: 10.1038/s41388-023-02680-z  0.699
2022 Lebeau B, Jangal M, Zhao T, Wong CK, Wong N, Cañedo EC, Hébert S, Aguilar-Mahecha A, Chabot C, Buchanan M, Catterall R, McCaffrey L, Deblois G, Kleinman C, Park M, et al. 3D chromatin remodeling potentiates transcriptional programs driving cell invasion. Proceedings of the National Academy of Sciences of the United States of America. 119: e2203452119. PMID 36037342 DOI: 10.1073/pnas.2203452119  0.331
2022 Wu Q, Nie DY, Ba-Alawi W, Ji Y, Zhang Z, Cruickshank J, Haight J, Ciamponi FE, Chen J, Duan S, Shen Y, Liu J, Marhon SA, Mehdipour P, Szewczyk MM, ... ... Deblois G, et al. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nature Chemical Biology. PMID 35578032 DOI: 10.1038/s41589-022-01024-4  0.675
2021 Fukano M, Park M, Deblois G. Metabolic Flexibility Is a Determinant of Breast Cancer Heterogeneity and Progression. Cancers. 13. PMID 34572926 DOI: 10.3390/cancers13184699  0.335
2021 Cepeda Cañedo E, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, Autexier C, Deblois G, Park M, Witcher M, Ursini-Siegel J. 66ShcA potentiates the cytotoxic response of triple negative breast cancers to PARP inhibitors. Jci Insight. PMID 33470989 DOI: 10.1172/jci.insight.138382  0.337
2020 Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, Haight J, Tonekaboni SAM, Fortier AM, Kuasne H, McKee TD, Mahmoud H, Kushida M, Cameron S, Dogan-Artun N, et al. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nature Communications. 11: 4205. PMID 32826891 DOI: 10.1038/S41467-020-18020-8  0.711
2020 Deblois G, Madani Tonekaboni SA, Grillo G, Martinez C, Kao YI, Tai F, Ettayebi I, Fortier AM, Savage P, Fedor AN, Liu X, Guilhamon P, Lima-Fernandes E, Murison A, Kuasne H, et al. Epigenetic switch-induced viral mimicry evasion in chemotherapy resistant breast cancer. Cancer Discovery. PMID 32546577 DOI: 10.1158/2159-8290.Cd-19-1493  0.753
2020 Michealraj KA, Kumar SA, Kim LJY, Cavalli FMG, Przelicki D, Wojcik JB, Delaidelli A, Bajic A, Saulnier O, MacLeod G, Vellanki RN, Vladoiu MC, Guilhamon P, Ong W, Lee JJY, ... ... Deblois G, et al. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell. PMID 32445698 DOI: 10.1016/J.Cell.2020.04.047  0.731
2019 Wu Q, Heidenreich D, Zhou S, Ackloo S, Krämer A, Nakka K, Lima-Fernandes E, Deblois G, Duan S, Vellanki RN, Li F, Vedadi M, Dilworth J, Lupien M, Brennan PE, et al. A chemical toolbox for the study of bromodomains and epigenetic signaling. Nature Communications. 10: 1915. PMID 31015424 DOI: 10.1038/S41467-019-09672-2  0.705
2018 Casey AE, Sinha A, Singhania R, Livingstone J, Waterhouse P, Tharmapalan P, Cruickshank J, Shehata M, Drysdale E, Fang H, Kim H, Isserlin R, Bailey S, Medina T, Deblois G, et al. Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities. The Journal of Cell Biology. PMID 29921600 DOI: 10.1083/Jcb.201804042  0.722
2017 Samuel N, Wilson G, Deblois G, Said BI, Fischer NW, Lemire M, Lou Y, Li W, Alexandrova R, Novokmet A, Tran J, Nichols KE, Finlay JL, Choufani S, Remke M, et al. Abstract NG05: TP53-mediated human cancer susceptibility is defined by epigenetic dysregulation of microRNA-34A Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ng05  0.592
2016 Boukhaled GM, Cordeiro B, Deblois G, Dimitrov V, Bailey SD, Holowka T, Domi A, Guak H, Chiu HC, Everts B, Pearce EJ, Lupien M, White JH, Krawczyk CM. The Transcriptional Repressor Polycomb Group Factor 6, PCGF6, Negatively Regulates Dendritic Cell Activation and Promotes Quiescence. Cell Reports. PMID 27498878 DOI: 10.1016/J.Celrep.2016.07.026  0.686
2016 Deblois G, Smith HW, Tam IS, Gravel SP, Caron M, Savage P, Labbé DP, Bégin LR, Tremblay ML, Park M, Bourque G, St-Pierre J, Muller WJ, Giguère V. ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nature Communications. 7: 12156. PMID 27402251 DOI: 10.1038/Ncomms12156  0.489
2016 Samuel N, Wilson G, Said BI, Pan A, Deblois G, Fischer NW, Alexandrova R, Casallo G, Paton T, Lupien M, Gariepy J, Merico D, Hudson TJ, Malkin D. Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network. Oncotarget. PMID 27391063 DOI: 10.18632/Oncotarget.10417  0.548
2014 Perry MC, Dufour CR, Eichner LJ, Tsang DW, Deblois G, Muller WJ, Giguère V. ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction. Molecular and Cellular Biology. 34: 4232-43. PMID 25246633 DOI: 10.1128/Mcb.00895-14  0.336
2014 Labbé DP, Nowak DG, Deblois G, Lessard L, Giguère V, Trotman LC, Tremblay ML. Prostate cancer genetic-susceptibility locus on chromosome 20q13 is amplified and coupled to androgen receptor-regulation in metastatic tumors. Molecular Cancer Research : McR. 12: 184-9. PMID 24379448 DOI: 10.1158/1541-7786.Mcr-13-0477  0.331
2013 McGuirk S, Gravel SP, Deblois G, Papadopoli DJ, Faubert B, Wegner A, Hiller K, Avizonis D, Akavia UD, Jones RG, Giguère V, St-Pierre J. PGC-1α supports glutamine metabolism in breast cancer. Cancer & Metabolism. 1: 22. PMID 24304688 DOI: 10.1186/2049-3002-1-22  0.441
2013 Schade B, Lesurf R, Sanguin-Gendreau V, Bui T, Deblois G, O'Toole SA, Millar EK, Zardawi SJ, Lopez-Knowles E, Sutherland RL, Giguère V, Kahn M, Hallett M, Muller WJ. β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Research. 73: 4474-87. PMID 23720052 DOI: 10.1158/0008-5472.Can-12-3925  0.441
2013 Deblois G, St-Pierre J, Giguère V. The PGC-1/ERR signaling axis in cancer Oncogene. 32: 3483-3490. PMID 23208510 DOI: 10.1038/Onc.2012.529  0.432
2013 Deblois G, Giguère V. Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Nature Reviews. Cancer. 13: 27-36. PMID 23192231 DOI: 10.1038/Nrc3396  0.484
2012 Lessard L, Labbé DP, Deblois G, Bégin LR, Hardy S, Mes-Masson AM, Saad F, Trotman LC, Giguère V, Tremblay ML. PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. Cancer Research. 72: 1529-37. PMID 22282656 DOI: 10.1158/0008-5472.Can-11-2602  0.419
2012 Deblois G, Giguère V. Cancer: Reprogramming clinical outcome. Nature. 481: 275-6. PMID 22258604 DOI: 10.1038/481275A  0.439
2011 Giguère V, Dufour CR, Eichner LJ, Deblois G, Cermakian N. Estrogen-Related Receptor α, the Molecular Clock, and Transcriptional Control of Metabolic Outputs Cold Spring Harbor Symposia On Quantitative Biology. 76: 57-61. PMID 22179984 DOI: 10.1101/Sqb.2011.76.011031  0.33
2011 Deblois G, Giguère V. Functional and physiological genomics of estrogen-related receptors (ERRs) in health and disease. Biochimica Et Biophysica Acta. 1812: 1032-40. PMID 21172432 DOI: 10.1016/J.Bbadis.2010.12.009  0.34
2010 Deblois G, Chahrour G, Perry MC, Sylvain-Drolet G, Muller WJ, Giguère V. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. Cancer Research. 70: 10277-87. PMID 20961995 DOI: 10.1158/0008-5472.Can-10-2840  0.426
2010 Wilson BJ, Tremblay AM, Deblois G, Sylvain-Drolet G, Giguère V. An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha. Molecular Endocrinology (Baltimore, Md.). 24: 1349-58. PMID 20484414 DOI: 10.1210/Me.2009-0441  0.364
2010 Giguère V, Eichner LJ, Deblois G. 4 Control of cancer cell metabolism by nuclear receptor-based transcriptional pathways Ejc Supplements. 8: 1-2. DOI: 10.1016/S1359-6349(10)70813-2  0.416
2009 Deblois G, Hall JA, Perry MC, Laganière J, Ghahremani M, Park M, Hallett M, Giguère V. Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. Cancer Research. 69: 6149-57. PMID 19622763 DOI: 10.1158/0008-5472.Can-09-1251  0.456
2008 Deblois G, Giguère V. Nuclear receptor location analyses in mammalian genomes: from gene regulation to regulatory networks. Molecular Endocrinology (Baltimore, Md.). 22: 1999-2011. PMID 18292239 DOI: 10.1210/Me.2007-0546  0.308
2005 Laganière J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguère V. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proceedings of the National Academy of Sciences of the United States of America. 102: 11651-6. PMID 16087863 DOI: 10.1073/Pnas.0505575102  0.458
2005 Laganière J, Deblois G, Giguère V. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 19: 1584-92. PMID 15831516 DOI: 10.1210/Me.2005-0040  0.448
2004 Carrier JC, Deblois G, Champigny C, Levy E, Giguère V. Estrogen-related receptor alpha (ERRalpha) is a transcriptional regulator of apolipoprotein A-IV and controls lipid handling in the intestine. The Journal of Biological Chemistry. 279: 52052-8. PMID 15466464 DOI: 10.1074/Jbc.M410337200  0.318
2003 Laganière J, Deblois G, Giguère V. Nuclear receptor target gene discovery using high-throughput chromatin immunoprecipitation. Methods in Enzymology. 364: 339-50. PMID 14631854 DOI: 10.1016/S0076-6879(03)64019-X  0.332
Show low-probability matches.